AbbVie (ABBV) said Monday the European Medicines Agency's Committee for Medicinal Products for Human Use has backed the approval of upadacitinib to treat...
The Standard & Poor's 500 index rose 6.4% this week as stocks began bouncing off the previous week's lows when the market benchmark entered bear market...
Price: 149.27, Change: -0.24, Percent Change: -0.16 ...
Morphic Holdings (MORF) said it received notice from AbbVie Inc.'s (ABBV) AbbVie Biotechnology terminating its Oct. 16, 2018, agreement with Morphic...
| Address | 1 North Waukegan Road North Chicago, Illinois 60064-6400 |
| Phone | +1.847.932.7900 |
| Number of Employees | 30,000 |
| Recent SEC Filing | 06/29/2022 8-K |
| Chairman & Chief Executive Officer | Richard A. Gonzalez |
| Vice Chairman & President | Robert A. Michael |
| Chief Financial Officer & Senior Vice President | Scott T. Reents |
| Chief Scientific Officer, Senior VP-R&D | Thomas J. Hudson |
| Price Open | $153.08 |
| Previous Close | $153.16 |
| 52 Week Range | $105.56 - 175.91 |
| Market Capitalization | $271.8 B |
| Shares Outstanding | 1.8 B |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major |
| Current Dividend / Yield | $1.41 / 3.67% |
| Dividend Ex-Date | 07/14/2022 |
| Dividend Pay-Date | 08/15/2022 |
| Dividend Yield 5 Year Average | 4.08% | Next Earnings Announcement | 07/29/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 22.07 |
| Earnings per Share | $8.17 |
| Beta vs. S&P 500 | N/A |
| Revenue | $32.8 B |
| Net Profit Margin | 21.86% |
| Return on Equity | 85.78% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
